Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Capital Expenditures: 2023-2025

Historic Capital Expenditures for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $1.1 million.

  • Immunome's Capital Expenditures fell 27.49% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 6.50%. This contributed to the annual value of $7.2 million for FY2024, which is 763.18% up from last year.
  • As of Q3 2025, Immunome's Capital Expenditures stood at $1.1 million, which was up 23.31% from $905,000 recorded in Q2 2025.
  • Immunome's Capital Expenditures' 5-year high stood at $3.7 million during Q1 2025, with a 5-year trough of $36,000 in Q3 2023.
  • Its 3-year average for Capital Expenditures is $1.2 million, with a median of $1.1 million in 2025.
  • In the last 5 years, Immunome's Capital Expenditures surged by 4,175.00% in 2024 and then slumped by 61.39% in 2025.
  • Over the past 3 years, Immunome's Capital Expenditures (Quarterly) stood at $349,000 in 2023, then surged by 222.64% to $1.1 million in 2024, then declined by 27.49% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $905,000 for Q2 2025, and $3.7 million during Q1 2025.